Neuroendocrinology
Original Paper
Evidence for Prolonged Suppression of Stress-Induced Release of Adrenocorticotropic Hormone and Corticosterone with a Brain-Enhanced Dexamethasone-Redox Delivery SystemAnderson W.R. · Simpkins J.W. · Brewster M.E. · Bodor N.S.College of Pharmacy and the Center for Drug Design and Delivery, University of Florida, Gainesville, Fla., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: July 28, 1988
Accepted: November 30, 1988
Published online: April 02, 2008
Issue release date: 1989
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Abstract
We have developed a redox system for brain-enhanced delivery of dexamethasone based on an interconvertible dihydropyridine d= pyridinium salt carrier. Dexamethasone, when combined with the lipoidal carrier, readily crosses the blood-brain barrier. The carrier, when oxidized, reduces its rate of exit from the brain. The aim of the study was to evaluate the capacity of a dexamethasone-chemical delivery system (DX-CDS) and dexamethasone (DEX) to suppress stress-induced elevations of plasma adrenocorticotropic hormone (ACTH) and corticosterone (CORT). Adult male Sprague-Dawley (CD) rats were administered either DX-CDS (10 mg/kg), an equimolar dose of DEX or the drug vehicle (2-hydroxypropyl-β-cyclodextrin) by a single tail vein injection. Rats then received either no stress or a restraint stress for a 5- or 15-min duration on days 1, 3, 5 or 7 after drug administration and trunk blood was rapidly collected. To assess peripheral effects of DX-CDS and DEX, 1 ml of blood was removed via orbital puncture and evaluated for total and differential leukocyte counts in a separate group of animals. Both DX-CDS and DEX were effective on day 1 in suppressing, by greater than 95%, ACTH secretion induced by a 5-min stress. However, DX-CDS was effective through day 5 (44% suppression) while DEX was not effective after 24 h. When 15 min of stress was applied, DX-CDS effected a significant ACTH suppression through 7 days while DEX was effective for only 3 days. DX-CDS was effective through day 7 (55%) in suppressing CORT after a 15-min stress while DEX was effective for 3 days only. Both DX-CDS and DEX produced similar profiles of changes in total and differential leukocyte counts. Rats treated with DX-CDS had higher brain levels of total dexamethasone (free dexamethasone plus the quaternary pyridinium ion form of the delivery system) than animals receiving DEX only. Concomitantly, blood and liver levels of dexamethasone were lower in DX-CDS rats through 6 h than rats receiving DEX only. These data suggest DX-CDS is longer acting than DEX in suppressing stress-induced rises of ACTH and concomitant elevations in corticosterone. These observations, together with evidence of lower peripheral distribution of dexamethasone from the DX-CDS, suggest that DX-CDS acts primarily through local brain-release of DEX.
© 1989 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: July 28, 1988
Accepted: November 30, 1988
Published online: April 02, 2008
Issue release date: 1989
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
